May 13, 2024, Shanghai. Innolake Biopharm (“InnolakeBio” or “Innolake”) announced that its Investigational New Drug (IND) application for ILB-3101 (anti-B7H3 ADC) has been cleared to initiate clinical trial in China by NMPA (National Medical Product Administration). ILB-3101 is in-house designed and developed by InnolakeBio, and is globally the first anti-B7H3 ADC with Eribulin as payload to enter clinical trial. InnolakeBio is in parallel preparing IND filing at US FDA, and about to initiate FIH (First In Human) trial soon according to its clinical strategy and development plan.
About ILB-3101
B7H3 is a B7 family member of immune checkpoint proteins, and is overexpressed in a broad spectrum of malignant tumors. It has become an attractive target for cancer therapies in recent years. ILB-3101, a potentially best-in-class ADC, was constructed by conjugating a potent microtubule inhibitor Eribulin (approved chemotherapy drug) to a proprietary anti-B7H3 mAb through a proprietary linker. This ADC molecule has been developed and preclinically evaluated as both the 1st line ADC treatment for patients whose cancer type is B7H3 positive and sensitive to Eribulin and later line ADC treatment for patients whose cancer are B7H3 positive but TopoI inhibitor (or other frequently used ADC payloads) resistant.
About Innolake
BioInnolake Biopharm is a clinical stage biotech company, dedicated to developing innovative medicines against cancer and autoimmune diseases and to improve life of patients around the world. Innolake was co-founded by two industry veterans, Dr. Mingde Xia (former Sr. Director of Global External Innovation at Johnson & Johnson) and Mr. Robert Chen (former founding member and Executive Vice President of Genor Biopharma, one of pioneering therapeutic antibody companies in China) in 2020. The company debuted with a top-tier and enthusiastic scientific & clinical development team and $40 million Series Pre-A and successfully raised a $20 million Series A1 in 2023. By continuously building proprietary technology platforms and R&D capabilities, Innolake places innovation at the cornerstone of its overall strategy. Through in-house R&D and partnering, Innolake has established a robust pipeline of first-in-class and best-in-class drug candidates, three of which have entered or is entering clinical trial stage. Innolake has strong industry recognition, and has been listed as one of most innovative biotech companies on several renowned China biopharmaceutical industry innovation lists.